Suriname’s Lobi Health Center Expands HIV Prevention and Cancer Screening Services
Paramaribo, Suriname – March 3, 2026 – The Lobi Health Center (formerly the Lobi Foundation), a leading provider of sexual and reproductive health (SRHR) services in Suriname, is celebrating 58 years of operation with an expansion of its preventative care offerings. This includes the introduction of Pre-Exposure Prophylaxis (PrEP) for HIV prevention and novel HPV self-sampling tests for improved cervical cancer screening access.
A History of Accessible SRHR Services
Founded on February 29, 1968, as a family planning initiative, Lobi Health Center has evolved into a multidisciplinary public health center serving tens of thousands of clients annually. The organization has pioneered accessible SRHR services, encompassing contraception, HIV testing, and cervical cancer screening, alongside education and empowerment programs for young people, women, and vulnerable populations. Lobi also actively contributes to the development of national SRHR policies [Lobi Suriname].
Expanding Preventative Care: PrEP and HPV Self-Testing
In alignment with the Sustainable Development Goals (SDGs) and national health priorities, Lobi Health Center is committed to expanding care throughout Suriname’s districts, currently reaching nine out of ten. A key component of this expansion is the introduction of PrEP, a highly effective medication for preventing HIV infection [IPPF Americas & the Caribbean].
To increase participation in cervical cancer screening and reduce barriers to access, Lobi Health Center is also implementing qualitative HPV self-sampling tests. Cervical cancer is most common in women between 30 and 49 years of age and is often caused by the Human Papillomavirus (HPV) [Lobi Suriname].
Commitment to Quality and Confidentiality
Nensy Bandhoe, General Manager of Lobi Health Center, emphasized the organization’s dedication to providing respectful and quality sexual and reproductive care, prioritizing privacy and confidentiality. “We continue to build a Suriname in which everyone has access to respectful and quality sexual and reproductive care, with attention to privacy and confidentiality,” she stated.
Collaboration and Impact
Lobi Health Center acknowledges the crucial support of its partners, including the Ministry of Health, Welfare and Labour, the Pan American Health Organization (PAHO), the United Nations Population Fund (UNFPA), and other cooperating organizations. Recent initiatives, such as screening nearly 700 women for high-risk HPV types in just three days, demonstrate the organization’s commitment to preventative care [srnieuws.com].
Looking Ahead
Lobi Health Center remains a vital player in Suriname’s healthcare landscape, dedicated to improving the sexual and reproductive health of its citizens through expanded services, innovative approaches, and strong partnerships. The introduction of PrEP and HPV self-testing marks a significant step forward in the country’s efforts to prevent HIV and cervical cancer [gfcnieuws.com].
Keep reading
- How a Non-Judgmental Dentist Changed My Life
- Face Lift Surgery vs. Ulthera: Which Lifting Method is Right for You?
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)
- Shift Supervisor Job at CVS Health – Bristol, Rhode Island (news-usa.today)